pyrroles has been researched along with Acquired Hyperostosis Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, KQ; Li, C; Liu, S; Sui, X; Tang, MW; Tian, XL; Xu, KF; Xu, WS | 1 |
| Cao, Y; Huo, J; Li, C; Li, Y; Li, Z; Yu, M; Zhang, W; Zhang, Y | 1 |
| Hao, W; Li, C; Luo, Y; Yang, Q; Zhang, W; Zhao, Y | 1 |
3 other study(ies) available for pyrroles and Acquired Hyperostosis Syndrome
| Article | Year |
|---|---|
Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome.
Topics: Acquired Hyperostosis Syndrome; Adult; Female; Humans; Janus Kinase 3; Lymphangioleiomyomatosis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2019 |
Efficacy of tofacitinib in synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a pilot study with clinical and MRI evaluation.
Topics: Acquired Hyperostosis Syndrome; Adult; Female; Humans; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2020 |
Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib.
Topics: Acquired Hyperostosis Syndrome; Adult; Antirheumatic Agents; Autoimmunity; Bone and Bones; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Immunologic Tests; Janus Kinase Inhibitors; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Tomography, Emission-Computed; Treatment Outcome | 2018 |